Zhu et al.49,50 reported that the glycosylation of PD-L1 on the surface of EVs is a prerequisite for its binding and interaction with PD-1, making glycosylated PD-L1 on patient EVs a more reliable potential tumor biomarker. Here, CD274 is linked to neoplasm.